首页> 外国专利> It includes the pure reactive compound of particle i.e. insoluble or be only very slightly soluble in water, pharmaceutical carrier itself that method, which prepares the pharmaceutical composition of carrier,

It includes the pure reactive compound of particle i.e. insoluble or be only very slightly soluble in water, pharmaceutical carrier itself that method, which prepares the pharmaceutical composition of carrier,

机译:它包括颗粒的纯净反应性化合物,即不溶于水或仅微溶于水,药物载体本身即制备载体药物组合物的方法,

摘要

The preparation method for providing the pharmaceutical composition of carrier includes the insoluble or moderately soluble of the pure reactive compound progress of particle in water or the mixture of at least two compound of particle shows such activity, and wherein active component is solid at room temperature. The manufacture craft is that the active material of the mixture of suspension or active material are homogenized gap by interior piston homogenizer and have average diameter to form particle, by photon correlation spectroscopy at 10 nanometers to 1,000 nanometer, so that group sum of the ratio of particle greater than 5 microns is less than 0.1 (number distribution is measured with Coulter-counter). The pharmaceutical composition for further disclosing carrier includes particle (pure 4- [N- 2-hyroxy-2-methylpropyl ethanolamine] -2), cis- two (7-bis-, 6-dimethylmorpholin-4-yl -6-phenylpteridine), carbamazepine, pantocaine or prednisolone have specified average diameter and particle ratio.
机译:提供载体的药物组合物的制备方法包括将纯的反应性化合物在水中或至少两种显示这种活性的颗粒的混合物中不溶或适度溶解,其中活性组分在室温下为固体。制造工艺是将悬浮液或活性物质混合物中的活性物质通过内部活塞均质器均匀化间隙,并通过光子相关光谱法在10纳米至1,000纳米范围内具有平均直径以形成颗粒,以使大于5微米的颗粒小于0.1(数量分布通过库尔特计数器测量)。用于进一步公开载体的药物组合物包括颗粒(纯的4- [N--2-羟基-2-甲基丙基乙醇胺] -2),顺式的两个(7-双-,6-二甲基吗啉-4-基-6-苯基哌啶) ,卡马西平,泛卡因或泼尼松龙具有规定的平均直径和颗粒比。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号